Evaluation the in vitro Anti-Sickle Cell Potential of Two Medicinal Plant Species, Rhynchospora corymbosa and Olax subscorpioïdea on the Inhibition of Falciformation of SS Genotype Erythrocytes

Abstract

Aims: Sickle cell disease is one of the world's leading genetic disorders. It is characterized by the presence of an abnormal hemoglobin HbS in the blood. The anomaly affects the primary structure of hemoglobin, through the substitution of valine for glutamic acid. In traditional medicine, two plant species, Rhynchospora corymbosa and Olax subscorpioïdea, are used to treat this condition.
 Place and Duration of Study: Agro-valuation Laboratory, Hematology Clinic laboratory of Cocody Hospital University (CHU), between June-Aout 2021 and June-July 2022.
 Methodology: Following a triphytochemical test, the effect of each species on the in vitro inhibition of SS erythrocyte falciformation was evaluated.
 Results: Thus an abundance of alkaloids, tannins, saponins, polyterpenes and sterols were found in the families of molecules identified in Rhynchospora corymbosa. As for the decocted Olax subscorpioïdea, in addition to the families of molecules identified in Rhynchospora corymbosa the polyphenols, leuco-anthocyanins and flavonoids were found. In addition, at an equal concentration of 0.312 mg/mL, decoctions of Rhynchospora corymbosa and Olax subscorpioïdea gave an inhibition rates of 80 and 84 % respectively. Both extracts showed activity on in vitro falciformation inhibition. This activity is thought to be due to the presence of chemical groups with anti-oxidant and anti-inflammatory properties.
 Conclusion: The use of Rhynchospora corymbosa and Olax subscorpioïdea in the treatment of sickle cell disease in Côte d'Ivoire would be justified.